title icon
Luminary’s Unique Approach to

Non-viral Autologous Cell Therapy

  • Use of novel transposon, with the potential to eliminate viral-based cell therapy issues
    • Ensuring no residual unbound virus in product doses
    • Shown to be safer than existing 1st-generation transposons
  • In-licensing advances in autologous cell therapies over previous generations of CARs & TCRs (for cancer and autoimmune disorders)
  • Team and early investors have previously built a successful cell therapy company